Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

12.11.24 20:30 Uhr

Werte in diesem Artikel
Aktien

86,72 CHF -0,32 CHF -0,37%

Indizes

1.185,3 PKT -2,7 PKT -0,23%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

7.339,8 PKT -25,7 PKT -0,35%

1.884,2 PKT -4,4 PKT -0,24%

11.392,4 PKT -22,4 PKT -0,20%

1.566,1 PKT -3,2 PKT -0,20%

15.199,3 PKT -30,9 PKT -0,20%

3.517,2 PKT 0,5 PKT 0,01%

4.251,0 PKT -69,9 PKT -1,62%

15.070,9 PKT -30,8 PKT -0,20%

6.857,5 PKT -12,0 PKT -0,17%

For the quarter ended September 2024, Alcon (ALC) reported revenue of $2.43 billion, up 5.6% over the same period last year. EPS came in at $0.81, compared to $0.66 in the year-ago quarter.The reported revenue represents a surprise of -0.78% over the Zacks Consensus Estimate of $2.45 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +12.50%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales by region- United States: $1.11 billion versus $1.10 billion estimated by two analysts on average. Net sales by region- International: $1.32 billion versus the two-analyst average estimate of $1.34 billion. The reported number represents a year-over-year change of +6.5%. Net Sales- Total Surgical: $1.34 billion compared to the $1.34 billion average estimate based on four analysts. The reported number represents a change of +4.9% year over year. Net Sales- Total Vision care: $1.10 billion versus $1.10 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change. Net Sales- Total Surgical- Consumables: $701 million versus the four-analyst average estimate of $700.88 million. The reported number represents a year-over-year change of +6.1%. Net Sales- Total Surgical- Equipment/other: $215 million versus $216.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.5% change. Net Sales- Total Vision Care- Contact lenses: $664 million compared to the $664.88 million average estimate based on four analysts. The reported number represents a change of +8.5% year over year. Net Sales- Total Vision Care- Ocular health: $431 million versus $438.87 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.9% change. Net Sales- Total Surgical- Implantables: $422 million compared to the $426.85 million average estimate based on four analysts. The reported number represents a change of +5.2% year over year. Revenues- Other revenues: $21 million versus the three-analyst average estimate of $20.25 million. View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned -5.1% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Novartis

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Novartis AG

Analysen zu Novartis AG

DatumRatingAnalyst
17.12.2024Novartis HoldDeutsche Bank AG
10.12.2024Novartis HoldDeutsche Bank AG
10.12.2024Novartis HoldJefferies & Company Inc.
05.12.2024Novartis HoldDeutsche Bank AG
03.12.2024Novartis NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
21.11.2024Novartis BuyUBS AG
14.11.2024Novartis BuyUBS AG
30.10.2024Novartis OutperformBernstein Research
30.10.2024Novartis BuyUBS AG
29.10.2024Novartis OutperformBernstein Research
DatumRatingAnalyst
17.12.2024Novartis HoldDeutsche Bank AG
10.12.2024Novartis HoldDeutsche Bank AG
10.12.2024Novartis HoldJefferies & Company Inc.
05.12.2024Novartis HoldDeutsche Bank AG
03.12.2024Novartis NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
21.11.2024Novartis UnderweightBarclays Capital
24.06.2024Novartis UnderweightBarclays Capital
23.04.2024Novartis UnderweightBarclays Capital
28.03.2024Novartis UnderweightBarclays Capital
06.02.2024Novartis UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"